Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 452-458

  Liao, Shu Yuan ^a,b   Darcy, Kathleen M ^c   Randall, Leslie M ^d   Tian, Chunqiao ^c   Monk, Bradley J ^d   Burger, Robert A ^d   Fruehauf, John P ^d   Peters, William A ^e   Stock, Richard J ^f   Stanbridge, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JOSEPH HOSPITAL   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

Author keywords

Carbonic anhydrase IX; Cervical cancer; GOG

Indexed keywords

CARBONATE DEHYDRATASE IX; CD31 ANTIGEN; CISPLATIN; ENDOGLIN; FLUOROURACIL; PROTEIN P53; THROMBOSPONDIN 1; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGE DISTRIBUTION; AGED; ANGIOGENESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL TYPE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EARLY CANCER; ENZYME ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UTERINE CERVIX; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 75749122186     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.062     Document Type: Article

References (41)

1. Parkin M.D., Bray F., Ferjay J., and Pisani P. Global cancer statistics 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. CA Cancer. J. Clin. 58 (2008) 71-96
3. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD. (http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007)
4. Delgado G., Bundy B., Zaino R., Sevin B.U., Creasman W.T., and Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. 38 (1990) 352-357
5. Burger R.A., Monk B.J., Kurosaki T., et al. Human papillomavirus type 18 association with poor prognosis in early stage cervical cancer. J. Natl. Cancer Inst. 88 (1996) 1361-1368
6. Monk B.J., Wang J., Im S., et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol. Oncol. 96 (2005) 721-728
7. Im S.S., Wilczynski S.P., Burger R.A., et al. Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion. Clin. Cancer Res. 9 (2003) 4145-4150
8. Zavada J., Zavadova Z., Pastorekova S., Ciampor F., Pastorek J., and Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int. J. Cancer 54 (1993) 268-274
9. Pastorek J., Pastorekova S., Callebaut I., Mornon J.P., Zelnik V., Opavsky R., et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9 (1994) 2877-2888
10. Liao S.Y., Brewer C., Zavada J., Pastorek J., Pastorekova S., Manetta A., et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinoma. Am. J. Pathol. 145 (1994) 598-609
11. Loncaster J.A., Harris A.L., Davidson S.E., Logue J.P., Hunter R.D., Wycoff C.C., et al. Carbonic anhydrase (CA-IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61 (2001) 6396-6399
12. Mayer A., Höckel M., and Vaupel P. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin. Cancer Res. 11 (2005) 7220-7225
13. Kim J.Y., Shin H.J., Kim T.H., Cho K.H., Shin K.H., Kim B.K., et al. Tumor-associated carbonic anhydrase are linked to metastases in primary cervical cancer. J. Cancer Res. Clin. Oncol. 132 (2006) 302-308
14. Kirkpatrick J.P., Rabbani Z.N., Bentley R.C., Hardee M.E., Karol S., Meyer J., et al. Elevated CAIX expression is associated with an increased risk of distant failure in early-stage cervical cancer. Biomarker Insights 3 (2008) 45-55
15. Lee S., Shin H.J., Han I.O., Hong E.K., Park S.Y., Roh J.W., et al. Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer. Cancer Sci. 98 (2007) 329-333
16. Lee W.Y., Huang S.C., Hsu K.F., Tzeng C.C., and Shen W.L. Roles for hypoxia-regulated genes during cervical carcinogenesis: Somatic evolution during the hypoxia-glycolysis-acidosis sequence. Gynecol. Oncol. 108 (2008) 377-384
17. Liao S.Y., Aurelio O.N., Jan K., Zavada J., and Stanbridge E.J. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 57 (1997) 2827-2831
18. Driessen A., Landuvt W., Pastorekova S., Moons J., Goethals L., Haustermans K., et al. Expression of carbonic anhydrase IX (CAIX, a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann. Surg. 243 (2006) 334-340
19. Saarnio J., Parkkila S., Parkklia A.K., Pastoreková S., Pastorek J., Kairaluoma M.I., et al. Immunohistochemical study of colorectal tumors for expression of novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol. 153 (1998) 279-285
20. Beasley N.J., Wykoff C.C., Watson P.H., Leek R., Turley H., Gatter K., et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 61 (2001) 5262-5267
21. Giatromanolaki A., Koukouakis M.I., Sivridis E., Pastorek J., Wykoff C.C., Gatter K.C., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 61 (2001) 7992-7998
22. Chia S.K., Wykoff C.C., Watson P.H., Han C., Leek R.D., Pastorek J., et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 19 (2001) 3660-3668
23. Ivanov S., Liao S.Y., Ivanova A., Danilkovitch-Miaqkova A., Tarasova N., Weirich G., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 158 (2001) 905-919
24. Hedley D., Pintillie M., Woo J., Morrison A., Birle D., Fyles A., et al. Carbonic anhydrase IX expression, hypoxia and prognosis in patients with uterine cervical carcinomas. Clin. Cancer Res. 9 (2003) 5666-5674
25. Hussain S.A., Palmer D.H., Ganesan R., Hiller L., Gregory J., Murray P.G., et al. Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol. Report 11 (2004) 1005-1010
26. Eriksen J., Overgaard J., and Head and Neck Cancer Study Group (DAHANCA). Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with know modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother. Oncol. 83 (2007) 383-388
27. Peters III W.A., Liu P.Y., Barrett Jr. R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 18 (2000) 1606-1613
28. Randall L.M., Monk B.J., Darcy K.M., Tian C., Burger R.A., Liao S.Y., et al. Markers of angiogenesis in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 112 (2009) 583-589
29. 2 from contingency tables, and the calculation of P. J. Royal. Stat. Soc. 85 (1922) 87-94
30. Mehta C.R., and Patel N.R. A network algorithm for performing Fisher's Exact Test in r × c contingency tables. J. Am. Stat. Assoc. 78 (1983) 427-434
31. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
32. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 50 (1966) 63-70
33. Peto R., and Peto J. Asymptotically efficient rank invariant test procedures. J. Royal Stat. Soc. Series A (General) 135 (1972) 185-207
34. Cox D.R. Regression models and life tables. J. Royal Stat. Soc. Series B 34 (1972) 187-220
35. Olive P.L., Aquini-Parsons C., MacPhail S.H., Liao S.Y., Raleigh J.A., Lerman M.I., et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 61 (2001) 8924-8929
36. Jankovic B., Aquino-Parsons C., Raleigh J.A., Stanbridge E.J., Durand R.E., Banath J.P., et al. Comparison between pimonidazole binding comparison between pimonidazole, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin. Cytom. 70 (2006) 45-55
37. Mayer A., Höckel M., and Vaupel P. Endogenous hypoxia markers in locally advanced cancers of the uterine cervic: reality or wishful thinking?. Strahlenther. Onkol. 182 (2006) 501-510
38. Tatum J.L., Kelloff G.J., Gilliews R.J., Arbeit J.M., Brown J.M., Chao K.S., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 82 (2006) 699-757
39. Pastorekova S., Kopacek J., and Pastorek J. Carbonic anhydrase inhibitors and the management of cancer. Curr. Top. Med. Chem. 7 (2007) 865-878
40. Winum J.Y., Rami M., Scozzafava A., Montero J.L., and Supuran C. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med. Res. Rev. 28 (2008) 445-463
41. Pastorekova S., Zatovicova M., and Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr. Pharm. Des. 14 (2008) 685-698